Table 2.
Methodological quality of included studies.
| Study | 11-item check list recommended by AHRQ | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| i | ii | iii | iv | v | vi | vii | viii | ix | x | xi | Score | Quality | |
| Wang et al. (44) |  |
|
|
|
|
|
6 | M | |||||
| Sarigül Sezenöz et al. (43) | |
|
|
|
|
5 | M | ||||||
| Lu et al. (42) | |
|
|
|
|
|
6 | M | |||||
| Hou et al. (41) | |
|
|
|
|
|
6 | M | |||||
| Kim et al. (40) | |
|
|
|
|
|
6 | M | |||||
| Aydogan et al. (39) | |
|
|
|
|
|
6 | M | |||||
| Akil et al. (38) | |
|
|
|
|
|
|
7 | M | ||||
| Kumar et al. (37) | |
|
|
|
|
|
|
7 | M | ||||
| Cennamo et al. (36) | |
|
|
|
|
|
6 | M | |||||
| Park et al. (35) | |
|
|
|
|
|
|
|
8 | H | |||
| Kim et al. (34) | |
|
|
|
|
|
|
7 | M | ||||
| Hwang et al. (33) | |
|
|
|
|
5 | M | ||||||
| Yamada et al. (32) | |
|
|
|
|
|
|
|
8 | H | |||
| Sung et al. (31) | |
|
|
|
|
|
|
7 | M | ||||
| Kim et al. (30) | |
|
|
|
|
|
|
|
8 | H | |||
| Kim et al. (29) | |
|
|
|
|
|
6 | M | |||||
| Holló et al. (48) | |
|
|
|
|
|
6 | M | |||||
| Arintawati et al. (28) | |
|
|
|
|
5 | M | ||||||
| Pomorska et al. (47) | |
|
|
|
|
|
6 | M | |||||
| Morooka et al. (27) | |
|
|
|
|
|
|
7 | M | ||||
| Horn et al. (26) | |
|
|
|
|
|
6 | M | |||||
| Garas et al. (46) | |
|
|
|
|
|
|
7 | M | ||||
| Taliantzis et al. (45) | |
|
|
|
|
5 | M | ||||||
AHRQ, Agency for Healthcare Research and Quality; H, high quality; M, moderate quality; L, low quality; high quality (score: 8–11); moderate quality (score: 4–7); low quality (score: 0–3). i, Define the source of information; ii, List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications; iii, Indicate time period used for identifying patients; iv, Indicate whether or not subjects were consecutive if not population-based; v, Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants; vi, Describe any assessments undertaken for quality assurance purposes; vii, Explain any patient exclusions from analysis; viii, Describe how confounding was assessed and/or controlled; ix, If applicable, explain how missing data were handled in the analysis; x, Summarize patient response rates and completeness of data collection; xi, Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained. means the study meets the requirements of the corresponding items.